Gilead Sciences Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Gilead Sciences hat ein Gesamteigenkapital von $17.5B und eine Gesamtverschuldung von $25.2B, wodurch sich der Verschuldungsgrad auf 144.3% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $56.3B bzw. $38.8B. Gilead Sciences Das EBIT des Unternehmens beträgt $9.9B, so dass der Zinsdeckungsgrad 17.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $6.1B.

Wichtige Informationen

144.3%

Verhältnis von Schulden zu Eigenkapital

US$25.19b

Verschuldung

Zinsdeckungsgrad	17.7x
Bargeld	US$5.52b
Eigenkapital	US$17.46b
Gesamtverbindlichkeiten	US$38.84b
Gesamtvermögen	US$56.29b

Jüngste Berichte zur Finanzlage

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Jun 13

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 17

Recent updates

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Jun 13

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

May 23

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Mar 01

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Feb 28

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Feb 15

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Feb 13

Gilead Sciences: Cheap For A Reason

Feb 10

Gilead Sciences: The Sky Is Not Falling

Feb 01

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Jan 15

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Dec 25

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 17

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: GILDDie kurzfristigen Aktiva des Unternehmens ($14.0B) übersteigen seine kurzfristigen Passiva ($13.0B).

Langfristige Verbindlichkeiten: GILDDie kurzfristigen Vermögenswerte des Unternehmens ($14.0B) decken seine langfristigen Verbindlichkeiten ($25.8B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: GILDDie Nettoverschuldung im Verhältnis zum Eigenkapital (109.6%) wird als hoch angesehen.

Schulden abbauen: GILDDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 120.3% auf 144.3% gestiegen.

Schuldendeckung: GILDDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (33.7%).

Zinsdeckung: Die Zinszahlungen für die Schulden von GILD sind durch das EBIT gut gedeckt (17.7x coverage).

Gilead Sciences Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Recent updates

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences: Cheap For A Reason

Fourth quarter dividend increased to US$0.77

Full year 2023 earnings: EPS misses analyst expectations

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences: The Sky Is Not Falling

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Upcoming dividend of US$0.75 per share at 3.8% yield

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen